RecruitingNot ApplicableNCT05899582

Extracranial-intracranial Bypass Surgery for Symptomatic Chronic Middle Cerebral Artery Occlusion: the CMOSS-2 Trial

Extracranial-intracranial Bypass Surgery Versus Medical Treatment Alone for Symptomatic Chronic Middle Cerebral Artery Occlusion: the CMOSS-2 Trial

Sponsor

Xuanwu Hospital, Beijing

Enrollment

420 participants

Start Date

Sep 15, 2023

Study Type

INTERVENTIONAL

Conditions

Symptomatic Chronic Middle Cerebral Artery Occlusion Infarction, Middle Cerebral Artery

Summary

The CMOSS-2 trial is a government-funded, prospective, multicenter, randomized controlled trial. It will recruit symptomatic chronic occlusion of the middle cerebral artery in patients with severe hemodynamic insufficiency. Only high-volume center with a proven track record will be included. Patients will be randomized (1:1) to best medical treatment alone or medical treatment plus bypass surgery. Primary outcome is ischemic stroke in the territory of the target artery within 24 months after randomization.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Extracranial-Intracranial Bypass Surgery and Medical treatment alone for people with infarction, middle cerebral artery and symptomatic chronic middle cerebral artery occlusion. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREExtracranial-Intracranial Bypass Surgery

Extracranial-intracranial bypass surgery plus medical treatment

OTHERMedical treatment alone

Best medical treatment alone according to current clinical guidelines, including antiplatelet drugs (e.g. aspirin) and risk factor controls.

Locations(1)

Xuanwu Hospital, Capital Medical University.

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05899582